Form 4: Maze Therapeutics Executive Trades Shares

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, executed a Rule 10b5-1 plan transaction involving the sale of 15,000 shares.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., reported a transaction on May 14, 2026.
• This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025.
• Bernstein acquired 15,000 shares of common stock at a price of $10.42 per share.
• Subsequently, 15,000 shares were disposed of at a weighted average price of $26.2236 per share, with individual sale prices ranging from $25.77 to $26.44.
• Following these transactions, Bernstein beneficially owns 222,407 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an executive sale can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic insider trading.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading activity.
• The sale occurred at a price significantly higher than the acquisition price, suggesting a profitable transaction for the executive.
• The executive still holds a substantial number of shares (222,407) after the reported transaction.

Negatives

• A significant number of shares (15,000) were sold by a key executive.
• The sale represents a disposal of equity, which could be interpreted negatively by the market if not contextualized by the 10b5-1 plan.

Risks

• Potential for negative market perception due to a key executive selling shares, even if under a pre-arranged plan.
• The specific reasons for the sale under the 10b5-1 plan are not detailed, leaving room for speculation.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on past transactions.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• The reported price for the sale of shares was a weighted average price, with sales occurring at prices ranging from $25.77 to $26.44 per share.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by executives is common practice to diversify holdings or meet financial obligations while mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders: May view the sale with caution, although the Rule 10b5-1 plan provides some reassurance against insider trading concerns.
• Employees: May interpret the sale as a sign of confidence or a need for liquidity by a key executive, depending on broader company performance.
• Management: The transaction is a routine part of executive compensation and portfolio management.

Next Steps

• Monitor future Form 4 filings for any additional transactions by Harold Bernstein or other Maze Therapeutics executives.
• Observe the company's stock performance and any related news following this disclosure.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Maze Therapeutics, Stock Sale, Executive Compensation, Beneficial Ownership